{
  "id": 18394765,
  "title": "Halozyme falls 6% as raised guidance fails to impress investors",
  "url": "https://urgent.news/2026/11/05/halozyme-falls-6-as-raised-guidance-fails-to-impress-investors",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-05T22:59:57.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/halozyme-falls-6-as-raised-guidance-fails-to-impress-investors-5006041"
  },
  "original_language": "en",
  "account": "Halozyme Therapeutics Inc (NASDAQ: HALO) experienced a 6% decline in shares on Thursday following the release of its third-quarter results. While the biotechnology company's adjusted earnings per share of $2.39 surpassed analyst expectations by $0.11, investors were less impressed with the raised full-year guidance. The company now anticipates revenue between $1.860 billion and $1.925 billion, with an adjusted EPS range of $8.75 to $9.05, both of which exceeded the consensus estimates. Despite robust growth in total revenue (39% YoY) and royalty revenue (44% YoY), the adjusted EBITDA guidance increase of 89% to 96% over 2025 failed to meet investor expectations. The improved performance included the expansion of ENHANZE collaboration agreements with three partners and the successful legal challenge against Merck over patent infringement.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}